Navigation Links
GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA
Date:3/14/2009

ARLINGTON, Va., March 14 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of the U.S. Food and Drug Administration (FDA).

"GPhA stands ready to work with Dr. Margaret Hamburg on the critical issues facing the Agency as it carries out its mission to protect the public health. Dr. Hamburg's outstanding experience both in government and the health care arena make her an excellent choice to lead the FDA. Now more than ever, FDA needs a strong, smart manager and Dr. Hamburg answers that call.

"As Deputy Commissioner, Dr. Joshua Sharfstein brings exceptional knowledge of what it takes to ensure the safety and efficacy of the medicines that Americans rely on to improve their health. His commitment to protecting the public health is stellar. As Commissioner and Deputy Commissioner, Drs. Hamburg and Sharfstein will work to give FDA scientists the resources they desperately need to uphold the Agency's gold standard of quality and safety.

"With Americans growing increasingly concerned about paying for needed medicines as the economy continues to struggle, it is critical that consumers have access to safe and affordable generic and biogeneric medicines. FDA scientists and reviewers are working hard every day to bring generic medicines to market, but the FDA's resources are simply stretched too thin and long-existing barriers to access must be eliminated. With generics saving government and consumers billions of dollars annually, we look forward to working with Dr. Hamburg to increase investments in the Agency and remove barriers that are keeping affordable medicines from getting to patients.

"The time has also come for Congress to give FDA the authority and flexibility to create a workable biogenerics approval pathway. President Obama stated in his budget proposal his desire to move the process forward and his action was followed by the bipartisan consensus bill introduced by Chairman Waxman, and Representatives Deal, Pallone and Emerson earlier this week. Dr. Hamburg's leadership will be instrumental in this effort.

"We also look forward to working with Drs. Hamburg and Sharfstein on a host of other important Agency issues including strengthening the foreign inspection system and addressing the proliferation of carve-out legislation being introduced in state capitols across the country. As we celebrate the 25th anniversary of the passage of the landmark Hatch-Waxman Act, the generic industry is rolling up its sleeves to work with the new FDA leadership, the Obama Administration and Congress in creating history again through passage of biogenerics legislation and strengthening our health care system."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
2. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
3. Pelosi Statement on President Obamas Executive Order on Stem Cell Research
4. AHIP Statement on White House Health Care Summit
5. Change to Win Statement on White House Health Care Forum
6. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California, Regarding President Obamas Healthcare Summit
7. AAJ Statement on Supreme Court Decision in Favor of Diana Levine
8. NJLRA Statement on Todays U.S. Supreme Courts Decision in Wyeth v. Levine
9. AAHSA Statement on Senate Special Committee on Aging Hearing, Health Reform in an Aging America
10. Pelosi Statement on President Obamas Nomination of Governor Sebelius as Secretary of HHS
11. AHIP Statement on Governor Sebelius and Nancy-Ann DeParle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... University of New England President Danielle ... of vice president of Student Engagement. In addition to his role as director ... life areas. , “In the space of just one year Jack has distinguished ...
(Date:4/28/2016)... ... 2016 , ... Cosmetic Town, an online plastic surgery community, announces the relaunch ... recently revamped and upgraded to allow even more interaction between doctors and patients as ... According to the senior editor of Cosmetic Town, “We are excited that our ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... of enterprise Data Center Infrastructure Management solutions, announces today the availability of ... enhancements in the area of capacity management and optimization, providing new analytical ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: